Summit Therapeutics Inc — Quarterly Cash Flow (NASDAQ:SMMT) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Total assets 502.85 M435.56 M383.82 M324.04 M261.73 M751.18 M Total liabilities 64.93 M46.81 M39.49 M64.6 M69.47 M92.32 M Total equity 437.92 M388.75 M344.33 M259.44 M192.26 M658.86 M Total liabilities & shareholders' equities 502.85 M435.56 M383.82 M324.04 M261.73 M751.18 M Total debt —————— Net debt ——————

新闻

RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View

H.C. Wainwright riduce il target di prezzo di Summit Therapeutics per l’incertezza sui tempi degli studi in Cina

H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty

SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Citizens conferma il rating su Summit Therapeutics per l’espansione della pipeline

Citizens reiterates Summit Therapeutics stock rating on pipeline expansion

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Summit Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-02-23

Summit Q4 2025: successi clinici oscurati da perdita EPS del 389%

Summit Q4 2025 slides: clinical wins offset by 389% EPS miss

Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss

Summit Therapeutics cala su mancato utile nonostante progressi